UY30192A1 - Nuevo uso - Google Patents
Nuevo usoInfo
- Publication number
- UY30192A1 UY30192A1 UY30192A UY30192A UY30192A1 UY 30192 A1 UY30192 A1 UY 30192A1 UY 30192 A UY30192 A UY 30192A UY 30192 A UY30192 A UY 30192A UY 30192 A1 UY30192 A1 UY 30192A1
- Authority
- UY
- Uruguay
- Prior art keywords
- och3
- fluoro
- prevention
- hydrogen
- treatment
- Prior art date
Links
- -1 4-ethylpiperazin-1-yl Chemical group 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78025206P | 2006-03-08 | 2006-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY30192A1 true UY30192A1 (es) | 2007-10-31 |
Family
ID=38475142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY30192A UY30192A1 (es) | 2006-03-08 | 2007-03-07 | Nuevo uso |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7576093B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1993550A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2009529041A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080114717A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101394851A (cg-RX-API-DMAC7.html) |
| AR (1) | AR059754A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007222199A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0708619A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2644751A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL193484A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2008011417A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20084182L (cg-RX-API-DMAC7.html) |
| TW (1) | TW200800203A (cg-RX-API-DMAC7.html) |
| UY (1) | UY30192A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007102770A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200807234B (cg-RX-API-DMAC7.html) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100137330A1 (en) * | 2007-03-08 | 2010-06-03 | Ratan Bhat | Use |
| RU2011123647A (ru) | 2008-11-10 | 2012-12-20 | Вертекс Фармасьютикалз Инкорпорейтед | Соединения, полезные в качестве ингибиторов atr киназы |
| HUE036068T2 (hu) | 2008-12-19 | 2018-06-28 | Vertex Pharma | ATR kináz gátlószereiként alkalmazható pirazinszármazékok |
| KR20120120307A (ko) * | 2010-01-19 | 2012-11-01 | 아스트라제네카 아베 | 피라진 유도체 |
| EP2569284B1 (en) | 2010-05-12 | 2015-07-08 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as inhibitors of atr kinase |
| US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| NZ603477A (en) | 2010-05-12 | 2014-09-26 | Vertex Pharma | Compounds useful as inhibitors of atr kinase |
| JP2013526538A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| US9062008B2 (en) | 2010-05-12 | 2015-06-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| AU2011270807A1 (en) | 2010-06-23 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of ATR kinase |
| MX2013011450A (es) | 2011-04-05 | 2014-02-03 | Vertex Pharma | Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr). |
| MX352975B (es) * | 2011-05-23 | 2017-12-15 | Merck Patent Gmbh | Piridina y derivados de pirazina. |
| JP2014522818A (ja) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| EP2723746A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| WO2012178123A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US8765751B2 (en) | 2011-09-30 | 2014-07-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US8846686B2 (en) | 2011-09-30 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| CN103957917A (zh) | 2011-09-30 | 2014-07-30 | 沃泰克斯药物股份有限公司 | 用atr抑制剂治疗胰腺癌和非小细胞肺癌 |
| WO2013049726A2 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Processes for making compounds useful as inhibitors of atr kinase |
| WO2013071088A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US8841450B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2013071094A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013071085A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
| EP2776422A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| NZ726671A (en) | 2012-04-05 | 2018-04-27 | Vertex Pharma | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
| US8999632B2 (en) | 2012-10-04 | 2015-04-07 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
| WO2014062604A1 (en) | 2012-10-16 | 2014-04-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP4534538A3 (en) | 2012-12-07 | 2025-06-11 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| PT3702443T (pt) | 2013-03-14 | 2022-02-17 | Massachusetts Inst Technology | Composições e métodos para expansão e cultura de células estaminais epiteliais |
| WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| CA2932757C (en) | 2013-12-06 | 2023-10-31 | Vertex Pharmaceuticals Incorporated | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
| CN103804312B (zh) * | 2014-02-17 | 2016-04-20 | 四川百利药业有限责任公司 | 一类氮杂环化合物及其制备方法和用途 |
| RU2719583C2 (ru) | 2014-06-05 | 2020-04-21 | Вертекс Фармасьютикалз Инкорпорейтед | Радиоактивно меченные производные 2-амино-6-фтор-n-[5-фтор-пиридин-3-ил]-пиразоло[1, 5-а]пиримидин-3-карбоксамида, используемые в качестве ингибитора atr киназы, препараты на основе этого соединения и его различные твердые формы |
| SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
| CA2959404A1 (en) | 2014-09-03 | 2016-03-10 | The Brigham And Women's Hospital, Inc. | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
| KR102678021B1 (ko) | 2015-09-30 | 2024-06-26 | 버텍스 파마슈티칼스 인코포레이티드 | Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물 |
| WO2017120543A1 (en) | 2016-01-08 | 2017-07-13 | Massachusetts Institute Of Technology | Production of differentiated enteroendocrine cells and insulin producing cells |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| SG10201910821XA (en) | 2016-12-30 | 2020-01-30 | Frequency Therapeutics Inc | 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells |
| US11617745B2 (en) | 2018-08-17 | 2023-04-04 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating FOXO |
| US11162071B2 (en) | 2018-08-17 | 2021-11-02 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating JAG-1 |
| WO2020163812A1 (en) | 2019-02-08 | 2020-08-13 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| AU2024294424A1 (en) * | 2023-07-14 | 2025-11-20 | Jazz Pharmaceuticals Therapeutics, Inc. | Methods of use of a liposomal composition comprising an atr inhibitor |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL145757A (en) | 2000-02-05 | 2007-12-03 | Vertex Pharma | History of pyrazole and pharmaceutical preparations containing them |
| SE0102438D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| SE0102439D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| EP1465610B1 (en) * | 2002-01-10 | 2008-12-31 | F. Hoffmann-La Roche Ag | Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation |
| ATE346070T1 (de) | 2002-03-05 | 2006-12-15 | Lilly Co Eli | Purinderivate als kinaseinhibitoren |
| SE0203752D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| AU2004274861A1 (en) * | 2003-06-06 | 2005-03-31 | Wyeth | Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby |
| WO2005039485A2 (en) * | 2003-08-13 | 2005-05-06 | Chiron Corporation | Gsk-3 inhibitors and uses thereof |
| US20050064044A1 (en) * | 2003-09-19 | 2005-03-24 | Georges Rawadi | GSK-3beta inhibitors in the treatment of bone-related diseases |
-
2007
- 2007-03-02 TW TW096107083A patent/TW200800203A/zh unknown
- 2007-03-06 WO PCT/SE2007/000216 patent/WO2007102770A1/en not_active Ceased
- 2007-03-06 MX MX2008011417A patent/MX2008011417A/es not_active Application Discontinuation
- 2007-03-06 CA CA002644751A patent/CA2644751A1/en not_active Abandoned
- 2007-03-06 AU AU2007222199A patent/AU2007222199A1/en not_active Abandoned
- 2007-03-06 EP EP07716035A patent/EP1993550A4/en not_active Withdrawn
- 2007-03-06 BR BRPI0708619-9A patent/BRPI0708619A2/pt not_active IP Right Cessation
- 2007-03-06 CN CNA2007800079632A patent/CN101394851A/zh active Pending
- 2007-03-06 JP JP2008558230A patent/JP2009529041A/ja active Pending
- 2007-03-06 AR ARP070100917A patent/AR059754A1/es not_active Application Discontinuation
- 2007-03-06 KR KR1020087021787A patent/KR20080114717A/ko not_active Withdrawn
- 2007-03-07 UY UY30192A patent/UY30192A1/es not_active Application Discontinuation
- 2007-03-08 US US11/683,458 patent/US7576093B2/en not_active Expired - Fee Related
-
2008
- 2008-08-14 IL IL193484A patent/IL193484A0/en unknown
- 2008-08-21 ZA ZA200807234A patent/ZA200807234B/xx unknown
- 2008-10-06 NO NO20084182A patent/NO20084182L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007102770A1 (en) | 2007-09-13 |
| ZA200807234B (en) | 2009-09-30 |
| EP1993550A1 (en) | 2008-11-26 |
| EP1993550A4 (en) | 2010-04-21 |
| BRPI0708619A2 (pt) | 2011-06-07 |
| IL193484A0 (en) | 2009-08-03 |
| NO20084182L (no) | 2008-12-05 |
| US20070213322A1 (en) | 2007-09-13 |
| WO2007102770A8 (en) | 2008-01-31 |
| MX2008011417A (es) | 2008-09-22 |
| TW200800203A (en) | 2008-01-01 |
| AR059754A1 (es) | 2008-04-30 |
| KR20080114717A (ko) | 2008-12-31 |
| CN101394851A (zh) | 2009-03-25 |
| US7576093B2 (en) | 2009-08-18 |
| JP2009529041A (ja) | 2009-08-13 |
| AU2007222199A1 (en) | 2007-09-13 |
| CA2644751A1 (en) | 2007-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY30192A1 (es) | Nuevo uso | |
| ECSP045193A (es) | "nuevos compuestos heterociclicos, activos como inhibidores de beta-lactamasas" | |
| TNSN08283A1 (en) | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | |
| ECSP055684A (es) | Antagonistas del receptor opiode | |
| PH12012501122A1 (en) | Pteridinones as inhibitors of polo-like kinase | |
| ATE437872T1 (de) | Proteinkinaseinhibitoren | |
| TW200720266A (en) | Benzodioxane and benzodioxolan derivatives and uses thereof | |
| CY1108230T1 (el) | Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri | |
| MY147786A (en) | Substituted morpholine and thiomorpholine derivatives | |
| MY169274A (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
| MX2009009238A (es) | Nuevos inhibidores de fosfodiesterasa. | |
| UA107459C2 (uk) | Карбоксамідні сполуки і їх застосування як інгібіторів кальпаїну | |
| MX2010004312A (es) | Derivados de 1,3,4-tiadiazol espiro-condensados para inhibir la actividad de quinesina de la proteina de quinesina del huso. | |
| MX2012006962A (es) | Inhibidores de la esfingosina quinasa. | |
| UY31159A1 (es) | Derivados de quinolina, métodos para su fabricación, composiciones farmacéuticas de los mismos y usos de los mismos | |
| AR035603A1 (es) | Derivados de piperazina, composicion farmaceutica que los comprende y el uso de los mismos para la fabricacion de un medicamento como agentes serotonergicos | |
| MX2007013624A (es) | Inhibidores de proteina cinasa. | |
| TW200806321A (en) | New therapeutic combinations for the treatment or prevention of psychotic disorders | |
| TW200800943A (en) | Indane derivatives as MCH receptor antagonists | |
| TW200833697A (en) | Spiro-piperidine derivatives | |
| TW200531694A (en) | Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists | |
| MX2009005544A (es) | Indoles. | |
| MX2009005541A (es) | Indoles que actuan como antagonistas del receptor v1a. | |
| GEP20115222B (en) | New pharmaceutical compounds | |
| MX2009000762A (es) | 4-arilalcoximetil-4-fenil piperidinas y su uso como antagonistas del receptor de neuroquinina para el tratamiento de trastornos del sistema nervioso central. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20170529 |